Novo Nordisk Adjusts 2025 Outlook Amid Market Challenges

The shares of Novo Nordisk A/S experienced a significant decline on Tuesday, following the release of its latest earnings report. The company announced a downward revision of its sales and operating profit outlook for the year 2025.

Revised Forecasts Signal Slower Growth

Previously in May, Novo Nordisk projected a sales growth ranging between 13% and 21%. However, this forecast has now been adjusted to a more modest range of 8% to 14%. Similarly, the operating profit growth estimates have been revised down from 16%-24% to 10%-16%.

Factors Behind the Guidance Cut

The company attributes this adjustment to several factors, including lower growth expectations for Wegovy in the US obesity market, reduced growth projections for Ozempic in the US GLP-1 diabetes market, and lower-than-anticipated penetration for Wegovy in select international markets.

At 1:23 pm CET, Novo Nordisk's stock was down by 15.15%, trading at 380.95 Danish kroner.